ASCO Conference Coverage
Featured Articles
(STAT) May 15, 2019 - Scientists have long known that a mutant form of the cell-signaling protein called KRAS causes cancer, but discovering drugs capable of blocking KRAS has proven difficult. The protein is spherical and nearly featureless — its structure has been compared to a tennis ball — leaving potential drugs with few, if...
Read Article
(2019 ASCO) May 15, 2019 - In a phase I/IB study of 29 patients, age 4.9 months to 20 years, with rare central nervous system tumors, neuroblastoma, or other solid tumors, responses to entrectinib, a novel targeted treatment, were seen in 12 of the 28 evaluable patients. The 12 pediatric patients who experienced a response to therapy had...
Read Article
Latest Articles
May 20, 2019
May 17, 2019
May 17, 2019
May 17, 2019
May 17, 2019
May 17, 2019
May 17, 2019
May 17, 2019
View More
News Commentary
Editor Image
17 May, 2019 | by
Trastuzumab deruxtecan makes Margetixumab clinically irrelevant
View Comment
Editor Image
18 Apr, 2019 | by Tomasz M. Beer, MD
Exciting to see the ARCHES clinical trial selected for the plenary session. We...
View Comment
View More
OBR Blog
By Lynne Lederman, PhD On this final day of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting we... Read more
June 05, 2018
by Lynne Lederman, PhD Several late-breaking abstracts were presented today at the 2018 American Society of Clinical... Read more
June 04, 2018